Press Release: aap is granted European patent for LOQTEQ(R), taking an important step toward global patent protection of the LOQTEQ(R) portfolio

aap Implantate AG / aap is granted European patent for LOQTEQ(R), taking an important step toward global patent protection of the LOQTEQ(R) portfolio . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE), a developer, manufacturer and distributor of innovative trauma products, announced that the European Patent Office will shortly grant it a key patent for the core technology of its LOQTEQ(R) locking and compression plate system. The European patent will protect the LOQTEQ(R) hole in its current marketing form and, with it, the technology's final development stage. The final patent grant now depends solely on the fulfilment of formal conditions such as payment of a patent fee. In the next step the European patent will be nationalised in many key markets in Europe and published in different languages. The LOQTEQ(R) technology will then enjoy direct patent protection in these countries. As aap Implantate AG was granted the corresponding US patent in October last year and the company also holds many other international LOQTEQ(R) patents, the European patent represents an important step towards a global patent protection for the LOQTEQ(R) portfolio.

"With this key patent for our innovative LOQTEQ(R) product family in the important European market we have reached another significant milestone", said Bruke Seyoum Alemu, CEO of aap Implantate AG. "One of aap's priorities is to build up a strong IP-based trauma portfolio around LOQTEQ(R). The grant of the patent enables us to further strengthen and extend our competitive position in the trauma sector."

The LOQTEQ(R) product family holds numerous international patents that protect certain aspects of the stable-angle compression technology. The claims that the patent protects have led to a unique design combined with a high level of biomechanical stability. Advantages in respect of explantability were generated at the same time by reducing the risk that cold-welding poses.

"The European patent is for us a further proof of the success of our philosophy of developing innovative technologies in close cooperation with our customers", Bruke Seyoum Alemu said. "Our focus is always on ensuring that the resulting products offer our customers not only clinical but also economic advantages and thereby generate a sustainable benefit."

About aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1886964

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   January 14, 2015 07:13 ET (12:13 GMT)- - 07 13 AM EST 01-14-15